The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - Blood pressure measurement, diagnosis and assessment of risk

Canadian Journal of Cardiology

Volumn 24, Issue 6, 2008, Pages 455-463

  Padwal, Raj S ^a,x   Hemmelgarn, Brenda R ^b   Khan, Nadia A ^c   Grover, Steven ^d   McAlister, Finlay A ^a   McKay, Donald W ^e   Wilson, Thomas ^f   Penner, Brian ^g   Burgess, Ellen ^b   Bolli, Peter ^h   Hill, Michael D ^b   Mahon, Jeff ⁱ   Myers, Martin G ^j   Abbott, Carl ^k   Schiffrin, Ernesto L ^l   Honos, George ^l   Mann, Karen ^m   Tremblay, Guy ⁿ   Milot, Alain ^o   Cloutier, Lyne ^p   Chockalingam, Arun ^q   Rabkin, Simon W ^c   Dawes, Martin ^r   Touyz, Rhian M ^s   Bell, Chaim ^t,u   Burns, Kevin D ^v   Ruzicka, Marcel ^v   Campbell, Norman R C ^b   Lebel, Marcel ^w   Tobe, Sheldon W ^t   more..

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

^e MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^f UNIVERSITY OF SASKATCHEWAN   (Canada)

^g UNIVERSITY OF MANITOBA   (Canada)

^h Ambulatory Internal Medicine Teaching Clinic   (Canada)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^k QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^l MCGILL UNIVERSITY   (Canada)

^m DALHOUSIE UNIVERSITY   (Canada)

ⁿ Service de Cardiologie

^o UNIVERSITÉ LAVAL   (Canada)

^p UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^q SIMON FRASER UNIVERSITY   (Canada)

^r MCGILL UNIVERSITY   (Canada)

^s OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^t UNIVERSITY OF TORONTO   (Canada)

^u ST MICHAEL'S HOSPITAL   (Canada)

^v UNIVERSITY OF OTTAWA   (Canada)

^w LAVAL UNIVERSITY   (Canada)

^x UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

Blood pressure; Diagnosis; Guidelines; High blood pressure; Hypertension; Risk factors

Indexed keywords

ANABOLIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL STIMULANT AGENT; COCAINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; GLYCYRRHIZA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIDODRINE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SEX HORMONE; TACROLIMUS; THIAZIDE DIURETIC AGENT;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CANADA; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; LABORATORY TEST; LIFESTYLE MODIFICATION; MEDLINE; ORGAN INJURY; PEER REVIEW; PHEOCHROMOCYTOMA; PRACTICE GUIDELINE; RENOVASCULAR HYPERTENSION; RISK ASSESSMENT; TARGET ORGAN; BLOOD PRESSURE; CLINICAL COMPETENCE; DIFFERENTIAL DIAGNOSIS; HEALTH CARE QUALITY; MEDICAL EDUCATION; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; STANDARD;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; CANADA; CLINICAL COMPETENCE; DIAGNOSIS, DIFFERENTIAL; EDUCATION, MEDICAL, CONTINUING; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC; PROGRAM EVALUATION; RISK ASSESSMENT;

EID: 46249097434     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(08)70619-6     Document Type: Article

References (35)

1. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-7.
2. Kannel WB. Blood pressure as a cardiovascular risk factor: Prevention and treatment. JAMA 1996;275:1571-6.
3. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.
4. Padwal RS, Hemmelgarn BR, McAlister FA, et al; for the Canadian Hypertension Education Program. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2007;23:529-38.
5. Khan NA, Hemmelgarn B, Padwal R, et al; for the Canadian Hypertension Education Program. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can J Cardiol 2007;23:539-50.
6. Zamke KB, Campbell NR, McAlister FA, Levine M; Canadian Hypertension Recommendations Working Group. A novel process for updating recommendations for managing hypertension: Rationale and methods. Can J Cardiol 2000;16:1094-102.
7. McAlister FA. The Canadian Hypertension Education Program - a unique Canadian initiative. Can J Cardiol 2006;22:559-64.
8. Hemmelgarn BR, McAlister FA, Myers MG, et al; Canadian Hypertension Education Program. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2005;21:645-56.
9. Topol EJ, Lauer MS. The rudimentary phase of personalised medicine: Coronary risk scores. Lancet 2003;362:1776-7.
10. Hemmelgarn BR, McAlister FA, Grover S, et al; Canadian Hypertension Education Program. The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2006;22:573-81.
11. Grover SA, Hemmelgarn B, Joseph L, Milot A, Tremblay G. The role of global risk assessment in hypertension therapy. Can J Cardiol 2006;22:606-13.
12. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation 1991;83:356-62.
13. Deber RB, Kraetschmer N, Irvine J. What role do patients wish to play in treatment decision making? Arch Intern Med 1996;156:1414-20.
14. D'Agostino RB Sr, Grundy S, Sullivan LM, Wilson P; CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. JAMA 2001;286:180-7.
15. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: New results from the Framingham study. Am Heart J 2000;139:272-81. (Erratum in 2002;143:21).
16. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention. Arch Intern Med 1998;158:655-62. (Erratum in 1998;158:1228).
17. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: Risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776-81.
18. Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: A model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-9. (Erratum in 2002;102:679).
19. Conroy RM, Pyorala K, Fitzgerald AP, et al; SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987-1003.
20. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13. (Erratum in 2003;361:1060).
21. Grover SA, Lowensteyn I, Joseph L, et al; Cardiovascular Health Evaluation to Improve Compliance and Knowledge Among Uninformed Patients (CHECK-UP) Study Group. Patient knowledge of coronary risk profile improves the effectiveness of dyslipidemia therapy: The CHECK-UP study: A randomized controlled trial. Arch Intern Med 2007;167:2296-303.
22. Sever PS, Dahlöf B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-58.
23. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 2007;369:201-7. (Erratum in 2007;369:1518).
24. Padwal R, Laupacis A. Antihypertensive therapy and incidence of type 2 diabetes: A systematic review. Diabetes Care 2004;27:247-55.
25. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342:905-12.
26. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9.
27. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK. Diabetes in treated hypertension is common and carries a high cardiovascular risk: Results from a 28-year follow-up. J Hypertens 2007;25:1311-7.
28. Barzilay JI, Davis BR, Cutler JA, et al; ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006;166:2191-201.
29. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR; SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005;95:29-35.
30. Aksnes TA, Kjeldsen SE, Rostrup M, Omvik P, Hua TA, Julius S. Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension 2007;50:467-73.
31. DREAM Trial Investigators; Bosch J, Yusuf S, Gerstein HC. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62.
32. Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL. Thiazide diuretics, potassium, and the development of diabetes: A quantitative review. Hypertension 2006;48:219-24.
33. Bongers V, Bakker J, Beutler JJ, Beek FJ, De Klerk JM. Assessment of renal artery stenosis: Comparison of captopril renography and gadolinium-enhanced breath-hold MR angiography. Clin Radiol 2000;55:346-53.
34. Grobner T, Prischl FC. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 2007;72:260-4.
35. Williams GJ, Macaskill P, Chan SF, et al. Comparative accuracy of renal duplex sonographic parameters in the diagnosis of renal artery stenosis: Paired and unpaired analysis. Am J Roentgenol 2007;188:798-811.